A month has gone by since the last earnings report for Incyte (INCY). Shares have added about 17.2% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to ...
Incyte’s Jakafi LOE overhang masked a quietly transforming, profitable biotech whose non‑Jakafi portfolio is now compounding fast enough to support a structural rerating, despite 2028 risks. Q3 2025 ...
Incyte Corporation is undervalued, with high revenue growth, strong margins, and a 12.7% upside to a $115 target price; rated Buy. INCY's Q3 results beat expectations, driven by Jakafi and Opzelura ...
Fintel reports that on November 24, 2025, Barclays maintained coverage of Incyte (NasdaqGS:INCY) with a Overweight recommendation. Analyst Price Forecast Suggests 7.38% Downside As of November 17, ...
He's casting a cosy spell over families at bedtime, reading Julia Donaldson and Axel Scheffler classic Room on the Broom Olivier and Critics’ Choice Award-winning actor, Jonathan Bailey is sprinkling ...
Jefferies analyst Kelly Shi maintained a Buy rating on Incyte today and set a price target of $120.00. Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest ...
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback